Base de dados : MEDLINE
Pesquisa : L01.178.682.192.836.535 [Categoria DeCS]
Referências encontradas : 1721 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 173 ir para página                         

  1 / 1721 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29172981
[Au] Autor:Peterson J; Budlong H; Affeldt T; Skiermont K; Kyllo G; Heaton A
[Ad] Endereço:1 Fairview Pharmacy Services, Minneapolis, Minnesota.
[Ti] Título:Biosimilar Products in the Modern U.S. Health Care and Regulatory Landscape.
[So] Source:J Manag Care Spec Pharm;23(12):1255-1259, 2017 Dec.
[Is] ISSN:2376-1032
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Biosimilars have the potential to greatly reduce medication costs in the United States. As of July 1, 2017, 5 biosimilars have been approved by the FDA, but only 2 are available for purchase. This commentary outlines the efforts of an integrated health system to ensure biosimilar accessibility and discusses the current challenges and future implications. We highlight the implementation of a health plan policy and how a health system's formulary committee can encourage use while considering provider perceptions and operational challenges. In addition, we provide our perspective on potential implications for pricing, site of care, and pharmacy dispensing practices based on our experience with regulatory hurdles and market trends. Overall, we believe biosimilars are a good thing for the health care system, but their expected benefit may not be realized for years to come. DISCLOSURES: No outside funding supported this work. Affeldt reports advisory board membership with Janssen, and Skiermont reports membership with Amgen and McKesson. The other authors have nothing to disclose. Peterson and Budlong contributed the study concept and design and wrote the manuscript. Affeldt, Skiermont, Kyllo, and Heaton reviewed and revised the manuscript.
[Mh] Termos MeSH primário: Medicamentos Biossimilares/administração & dosagem
Prestação Integrada de Cuidados de Saúde/organização & administração
Aprovação de Drogas
[Mh] Termos MeSH secundário: Medicamentos Biossimilares/economia
Prestação Integrada de Cuidados de Saúde/economia
Custos de Medicamentos
Formulários Farmacêuticos como Assunto
Acesso aos Serviços de Saúde
Seres Humanos
Assistência Farmacêutica/organização & administração
Comitê de Farmácia e Terapêutica
Estados Unidos
United States Food and Drug Administration
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biosimilar Pharmaceuticals)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180201
[Lr] Data última revisão:
180201
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171128
[St] Status:MEDLINE
[do] DOI:10.18553/jmcp.2017.23.12.1255


  2 / 1721 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28119403
[Au] Autor:Ivanovska V; Leufkens HG; Rademaker CM; Zisovska E; Pijnenburg MW; van Dijk L; Mantel-Teeuwisse AK
[Ad] Endereço:Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.
[Ti] Título:Are age-appropriate antibiotic formulations missing from the WHO list of essential medicines for children? A comparison study.
[So] Source:Arch Dis Child;102(4):352-356, 2017 Apr.
[Is] ISSN:1468-2044
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: There is a global call for formulations, which are better suited for children of different age categories and in a variety of settings. One key public health area of interest is age-appropriate paediatric antibiotics. We aimed to identify clinically relevant paediatric formulations of antibiotics listed on pertinent formularies that were not on the WHO Essential Medicines List for Children (EMLc). METHODS: We compared four medicines lists versus the EMLc and contrasted paediatric antibiotic formulations in relation to administration routes, dosage forms and/or drug strengths. The additional formulations on comparator lists that differed from the EMLc formulations were evaluated for their added clinical values and costs. RESULTS: The analysis was based on 26 EMLc antibiotics. Seven oral and two parenteral formulations were considered clinically relevant for paediatric use. Frequently quoted benefits of oral formulations included: filling the gap of unmet therapeutic needs in certain age/weight groups (phenoxymethylpenicillin and metronidazole oral liquids, and nitrofurantoin capsules), and simplified administration and supply advantages (amoxicillin dispersible tablets, clyndamycin capsules, cloxacillin tablets, and sulfamethoxazole+trimethoprim tablets). Lower doses of ampicillin and cefazolin powder for injection could simplify the dosing in newborns and infants, reduce the risk of medical errors, and decrease the waste of medicines, but may target only narrow age/weight groups. CONCLUSIONS: The identified additional formulations of paediatric antibiotics on comparator lists may offer clinical benefits for low-resource settings, including simplified administration and increased dosing accuracy. The complexity of both procuring and managing multiple strengths and formulations also needs to be considered.
[Mh] Termos MeSH primário: Antibacterianos/uso terapêutico
Composição de Medicamentos
Medicamentos Essenciais
[Mh] Termos MeSH secundário: Fatores Etários
Criança
Vias de Administração de Medicamentos
Formulários Farmacêuticos como Assunto
Seres Humanos
Organização Mundial da Saúde
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Drugs, Essential)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170605
[Lr] Data última revisão:
170605
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170126
[St] Status:MEDLINE
[do] DOI:10.1136/archdischild-2016-311933


  3 / 1721 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28089415
[Au] Autor:Long MJ; LaPlant BN; McCormick JC
[Ti] Título:Antimicrobial stewardship in the Federal Bureau of Prisons: Approaches from the national and local levels.
[So] Source:J Am Pharm Assoc (2003);57(2):241-247, 2017 Mar - Apr.
[Is] ISSN:1544-3450
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: To determine the impact of national and local antimicrobial stewardship measures on overall antibiotic prescribing in the Federal Bureau of Prisons (BOP). SETTING: Care was delivered to more than 160,000 inmates in 122 BOP facilities in the United States and Puerto Rico. PRACTICE DESCRIPTION: Medical centers and health services clinics staffed by in-house medical staff, consultants, and specialists. Staffs include a variety of disciplines, including physicians, pharmacists, dentists, nurses, infection control personnel, therapists, health services administrators, and institution executive staff. PRACTICE INNOVATION: Innovations occurred on 2 levels: local components were used to reinforce national initiatives. Local institutions used a multidisciplinary team approach including education and focused evaluations of all antibiotic prescriptions before dispensing. National initiatives included the development of a closed formulary, clinical practice guidelines, an antimicrobial stewardship group led by pharmacy, development of tools and strategies for institutions, inclusion in the BOP strategic plan, and a drug utilization evaluation. EVALUATION: This was a study of antimicrobial stewardship within BOP and the resultant impact on antibiotic prescriptions. In addition, one institution's antimicrobial stewardship methods were reviewed to determine the impact on antibiotic prescribing practices. RESULTS: The total number of antibiotic prescriptions in BOP-managed institutions in fiscal year (FY) 2010 (October 2009 to September 2010) was 142,907 and progressively decreased to 105,832 in FY2015. The number of antibiotic prescriptions per 1000 inmates correspondingly decreased from 829 in FY2010 to 625 in FY2015. The overall number of antibiotic prescriptions as a percentage of total prescriptions decreased from 7.64% in FY2010 to 5.84% in FY2015. CONCLUSION: A robust multidisciplinary antimicrobial stewardship program has likely contributed to a decrease in both the total number and the rate of antibiotic prescriptions on a per-1000-patient basis in BOP.
[Mh] Termos MeSH primário: Antibacterianos/uso terapêutico
Guias de Prática Clínica como Assunto
Padrões de Prática Médica/normas
Prisões
[Mh] Termos MeSH secundário: Adulto
Revisão de Uso de Medicamentos
Feminino
Formulários Farmacêuticos como Assunto
Seres Humanos
Comunicação Interdisciplinar
Masculino
Assistência Farmacêutica/organização & administração
Desenvolvimento de Programas
Estados Unidos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170904
[Lr] Data última revisão:
170904
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170117
[St] Status:MEDLINE


  4 / 1721 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27981567
[Au] Autor:Cristofaro JV; Ansher SS; Zwiebel JA; Ivy P; Conley B; Abrams JS; Doroshow JH
[Ad] Endereço:Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, Maryland, USA.
[Ti] Título:National Cancer Institute Formulary: A Public-Private Partnership Providing Investigators Access to Investigational Anticancer Agents.
[So] Source:Clin Pharmacol Ther;101(5):616-618, 2017 May.
[Is] ISSN:1532-6535
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:As part of the White House Cancer Moonshot Initiative, the National Cancer Institute (NCI) has developed a drug formulary to provide investigational anticancer agents to the extramural research community. This article describes how the NCI Formulary functions, how researchers may apply for access to drugs in the formulary, and the NCI's initial goals for formulary participation. Approved investigators may apply for access to formulary agents at: https://nciformulary.cancer.gov.
[Mh] Termos MeSH primário: Antineoplásicos
Drogas em Investigação
Formulários Farmacêuticos como Assunto
National Cancer Institute (U.S.)
Parcerias Público-Privadas
[Mh] Termos MeSH secundário: Seres Humanos
Neoplasias/tratamento farmacológico
Estados Unidos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Drugs, Investigational)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170425
[Lr] Data última revisão:
170425
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:161217
[St] Status:MEDLINE
[do] DOI:10.1002/cpt.585


  5 / 1721 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27799154
[Au] Autor:van der Zanden TM; de Wildt SN; Liem Y; Offringa M; de Hoog M; Dutch Paediatric Pharmacotherapy Expertise Network NKFK (Nederlands Kenniscentrum voor Farmacotherapie bij Kinderen)
[Ad] Endereço:Department of Paediatrics, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands.
[Ti] Título:Developing a paediatric drug formulary for the Netherlands.
[So] Source:Arch Dis Child;102(4):357-361, 2017 Apr.
[Is] ISSN:1468-2044
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:As many drugs in paediatrics are used off-label, prescribers face a lack of evidence-based dosing guidelines. A Dutch framework was developed to provide dosing guidelines based on best available evidence from registration data, investigator-initiated research, professional guidelines, clinical experience and consensus. This has clarified the scientific grounds of drug use for children and encouraged uniformity in prescribing habits in the Netherlands. The developed framework and the current content of the Dutch Paediatric Formulary could be used as basis for similar initiatives worldwide, preferably in a concerted effort to ultimately provide children with effective and safe drug therapy.
[Mh] Termos MeSH primário: Formulários Farmacêuticos como Assunto
[Mh] Termos MeSH secundário: Criança
Consenso
Esquema de Medicação
Aprovação de Drogas
Medicina Baseada em Evidências
Seres Humanos
Bases de Conhecimento
Países Baixos
Uso Off-Label
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170605
[Lr] Data última revisão:
170605
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:161102
[St] Status:MEDLINE
[do] DOI:10.1136/archdischild-2016-311674


  6 / 1721 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27579915
[Au] Autor:Yeung K; Basu A; Hansen RN; Watkins JB; Sullivan SD
[Ad] Endereço:*Pharmaceutical Outcomes Research and Policy Program, University of Washington †Department of Health Services, School of Public Health, University of Washington, Seattle ‡Premera Blue Cross, Mountlake Terrace, WA.
[Ti] Título:Impact of a Value-based Formulary on Medication Utilization, Health Services Utilization, and Expenditures.
[So] Source:Med Care;55(2):191-198, 2017 Feb.
[Is] ISSN:1537-1948
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Value-based benefit design has been suggested as an effective approach to managing the high cost of pharmaceuticals in health insurance markets. Premera Blue Cross, a large regional health plan, implemented a value-based formulary (VBF) for pharmaceuticals in 2010 that explicitly used cost-effectiveness analysis (CEA) to inform medication copayments. OBJECTIVE OF THE STUDY: The objective of the study was to determine the impact of the VBF. DESIGN: Interrupted time series of employer-sponsored plans from 2006 to 2013. SUBJECTS: Intervention group: 5235 beneficiaries exposed to the VBF. CONTROL GROUP: 11,171 beneficiaries in plans without any changes in pharmacy benefits. INTERVENTION: The VBF-assigned medications with lower value (estimated by CEA) to higher copayment tiers and assigned medications with higher value to lower copayment tiers. MEASURES: Primary outcome was medication expenditures from member, health plan, and member plus health plan perspectives. Secondary outcomes were medication utilization, emergency department visits, hospitalizations, office visits, and nonmedication expenditures. RESULTS: In the intervention group after VBF implementation, member medication expenditures increased by $2 per member per month (PMPM) [95% confidence interval (CI), $1-$3] or 9%, whereas health plan medication expenditures decreased by $10 PMPM (CI, $18-$2) or 16%, resulting in a net decrease of $8 PMPM (CI, $15-$2) or 10%, which translates to a net savings of $1.1 million. Utilization of medications moved into lower copayment tiers increased by 1.95 days' supply (CI, 1.29-2.62) or 17%. Total medication utilization, health services utilization, and nonmedication expenditures did not change. CONCLUSIONS: Cost-sharing informed by CEA reduced overall medication expenditures without negatively impacting medication utilization, health services utilization, or nonmedication expenditures.
[Mh] Termos MeSH primário: Uso de Medicamentos/economia
Honorários Farmacêuticos/estatística & dados numéricos
Formulários Farmacêuticos como Assunto
Serviços de Saúde/utilização
Medicamentos sob Prescrição/economia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Criança
Pré-Escolar
Custo Compartilhado de Seguro
Financiamento Pessoal
Gastos em Saúde/estatística & dados numéricos
Seres Humanos
Lactente
Recém-Nascido
Seguro de Serviços Farmacêuticos/economia
Meia-Idade
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Prescription Drugs)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170515
[Lr] Data última revisão:
170515
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160901
[St] Status:MEDLINE
[do] DOI:10.1097/MLR.0000000000000630


  7 / 1721 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28339369
[Au] Autor:Allen LV
[Ad] Endereço:International Journal of Pharmaceutical Compounding. lallen@ijpc.com.
[Ti] Título:PreScription: Stability Studies and United States Pharmacopeia-National Formulary-Grade Chemicals.
[So] Source:Int J Pharm Compd;20(5):356, 2016 Sep-Oct.
[Is] ISSN:1092-4221
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Estabilidade de Medicamentos
Formulários Farmacêuticos como Assunto
Farmacopeias como Assunto
[Mh] Termos MeSH secundário: Estados Unidos
[Pt] Tipo de publicação:EDITORIAL
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171103
[Lr] Data última revisão:
171103
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170325
[St] Status:MEDLINE


  8 / 1721 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27700211
[Au] Autor:Bowlus CL; Kenney JT; Rice G; Navarro R
[Ti] Título:Primary Biliary Cholangitis: Medical and Specialty Pharmacy Management Update.
[So] Source:J Manag Care Spec Pharm;22(10-a-s Suppl):S3-S15, 2016 Oct.
[Is] ISSN:2376-1032
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Chronic liver disease and cirrhosis are a leading cause of morbidity and mortality in the United States. Primary biliary cholangitis (PBC), previously known as primary biliary cirrhosis and which has been designated an orphan condition, is a chronic autoimmune disease resulting in the destruction of the small bile ducts in the liver. Without effective treatment, disease progression frequently leads to liver failure and death. Until May 2016, the only FDA-approved treatment for PBC was ursodiol (UDCA), an oral hydrophilic bile acid, which can slow progression of liver damage due to PBC. However, 1 out of 3 patients taking UDCA has an inadequate biochemical response, leading to increased risk of disease progression, liver transplantation, and mortality. Given this unmet clinical need, new therapies are in development for the treatment of PBC. To provide pharmacists with an overview of the latest research on the pathophysiology of PBC and potential new treatment options and to highlight medical and specialty pharmacy approaches to managing access to drugs to treat orphan diseases such as PBC, a 2-hour satellite symposium was presented in conjunction with the 2015 Academy of Managed Care Pharmacy (AMCP) Nexus meeting. Although obeticholic acid was approved by the FDA for the treatment of PBC in May 2016, this development occurred after the symposium presentation. The symposium was supported by an independent educational grant from Intercept Pharmaceuticals and was managed by Analysis Group. Robert Navarro, PharmD, moderated the CPE-accredited symposium titled "Medical and Specialty Pharmacy Management Update on Primary Biliary Cirrhosis." Expert panelists included Christopher L. Bowlus, MD; James T. Kenney, RPh, MBA; and Gary Rice, RPh, MS, MBA, CSP. OBJECTIVE: To summarize the educational satellite symposium presentations and discussions. SUMMARY: Autoimmune liver diseases, including PBC, are responsible for 15% of all liver transplants performed and an equal percentage of deaths related to liver disease. UDCA is the only FDA-approved therapy for treatment of PBC and is considered the standard of care. Nevertheless, many patients do not respond to UDCA, creating the need for new therapeutic options to improve clinical outcomes for PBC patients with inadequate response to treatment. While several agents are being studied in combination with UDCA, monotherapy with the novel agent obeticholic acid, a farnesoid X receptor agonist, has also shown promising results. Health plans are anticipated to assign any newly introduced therapy for the treatment of PBC to specialty pharmacy given its orphan disease status. This assignment enables the health plan to receive disease education, which is particularly important when new drugs are indicated for orphan diseases, and assistance with designing appropriate prior authorization criteria. The clinical value of any new therapeutic options that will inform formulary decisions and prior authorization criteria will be assessed based on evidence of efficacy, safety, and tolerability, among other factors, such as the potential to reduce or delay medical resource utilization (e.g., liver transplant). Key considerations for prior authorization of a new therapy will be determining which PBC patients are appropriate candidates for the new therapy and developing criteria for that determination. These are likely to include clinical diagnostic criteria and degree of response to prior treatment with UDCA. Initially, any new therapy would likely be positioned as noncovered until appropriate prior authorization criteria are established. CONCLUSIONS: PBC is a chronic liver disease with significant morbidity and mortality, as well as a significant burden on the health care system if the disease progresses to the point at which a liver transplant is needed. Although UDCA, the current standard of care, has improved outcomes for many patients, others have an inadequate response to this treatment. This symposium discussed these issues and also addressed the overall treatment paradigm for orphan drug therapies, key implications for patient management, and the role of specialty pharmacy management and any associated needs both in general and specifically for new therapeutic options for PBC.
[Mh] Termos MeSH primário: Ácido Quenodesoxicólico/análogos & derivados
Colagogos e Coleréticos/uso terapêutico
Colangite/tratamento farmacológico
Medicina Baseada em Evidências
Doenças Raras/tratamento farmacológico
Receptores Citoplasmáticos e Nucleares/agonistas
Ácido Ursodesoxicólico/uso terapêutico
[Mh] Termos MeSH secundário: Ácido Quenodesoxicólico/efeitos adversos
Ácido Quenodesoxicólico/economia
Ácido Quenodesoxicólico/uso terapêutico
Colagogos e Coleréticos/efeitos adversos
Colagogos e Coleréticos/economia
Colangite/economia
Colangite/fisiopatologia
Congressos como Assunto
Progressão da Doença
Resistência a Medicamentos
Quimioterapia Combinada/efeitos adversos
Quimioterapia Combinada/economia
Educação Continuada em Farmácia
Doença Hepática Terminal/economia
Doença Hepática Terminal/etiologia
Doença Hepática Terminal/prevenção & controle
Doença Hepática Terminal/cirurgia
Formulários Farmacêuticos como Assunto
Seres Humanos
Cobertura do Seguro
Seguro de Serviços Farmacêuticos
Transplante de Fígado/efeitos adversos
Transplante de Fígado/educação
Meia-Idade
Honorários por Prescrição de Medicamentos
Doenças Raras/economia
Doenças Raras/fisiopatologia
Receptores Citoplasmáticos e Nucleares/metabolismo
Comunicações Via Satélite
Ácido Ursodesoxicólico/efeitos adversos
Ácido Ursodesoxicólico/economia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Cholagogues and Choleretics); 0 (Receptors, Cytoplasmic and Nuclear); 0 (farnesoid X-activated receptor); 0462Z4S4OZ (obeticholic acid); 0GEI24LG0J (Chenodeoxycholic Acid); 724L30Y2QR (Ursodeoxycholic Acid)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170413
[Lr] Data última revisão:
170413
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161005
[St] Status:MEDLINE


  9 / 1721 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27654562
[Au] Autor:Bellerby A; Needham DS
[Ad] Endereço:Health sciences, University of York, York, England.
[Ti] Título:Using the British National Formulary effectively.
[So] Source:Nurs Stand;31(4):56-62, 2016 Sep 21.
[Is] ISSN:2047-9018
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Nursing students, nurses and other healthcare professionals involved in prescribing, dispensing, administration and monitoring of medicines should be able to navigate and use the British National Formulary (BNF) effectively. Recent changes to the structure of the BNF have resulted in new symbols, additional sections in drug and drug-class monographs, and a reduction in the amount of cross-referencing between chapters. This article explores how healthcare professionals can access the information in the BNF to ensure that medicines use is optimised, therapeutic effects are maximised, and adverse drug reactions and drug interactions are minimised.
[Mh] Termos MeSH primário: Sistemas de Notificação de Reações Adversas a Medicamentos
Serviços de Informação sobre Medicamentos
Prescrições de Medicamentos
Formulários Farmacêuticos como Assunto
[Mh] Termos MeSH secundário: Interações Medicamentosas
Seres Humanos
Adesão à Medicação
Papel do Profissional de Enfermagem
Reino Unido
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170717
[Lr] Data última revisão:
170717
[Sb] Subgrupo de revista:N
[Da] Data de entrada para processamento:160923
[St] Status:MEDLINE
[do] DOI:10.7748/ns.2016.e10472


  10 / 1721 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27561002
[Au] Autor:Green AK; Wood WA; Basch EM
[Ad] Endereço:Cancer Outcomes Research Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill.
[Ti] Título:Time to Reassess the Cancer Compendia for Off-label Drug Coverage in Oncology.
[So] Source:JAMA;316(15):1541-1542, 2016 Oct 18.
[Is] ISSN:1538-3598
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Centers for Medicare and Medicaid Services (U.S.)/normas
Cloridrato de Erlotinib/uso terapêutico
Formulários Farmacêuticos como Assunto/normas
Oncologia/normas
Neoplasias/tratamento farmacológico
Uso Off-Label/normas
Inibidores de Proteínas Quinases/uso terapêutico
[Mh] Termos MeSH secundário: Bevacizumab/uso terapêutico
Cetuximab/uso terapêutico
Seres Humanos
Literatura de Revisão como Assunto
Estados Unidos
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Protein Kinase Inhibitors); 2S9ZZM9Q9V (Bevacizumab); DA87705X9K (Erlotinib Hydrochloride); PQX0D8J21J (Cetuximab)
[Em] Mês de entrada:1611
[Cu] Atualização por classe:161230
[Lr] Data última revisão:
161230
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:160826
[St] Status:MEDLINE
[do] DOI:10.1001/jama.2016.12770



página 1 de 173 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde